Quick Answer
Monopar Therapeutics reported Research And Development Expense of $9.90 million for the year ending 2025.
- Monopar Therapeutics showed a decrease of -23.8% in Research And Development Expense from 2024 to 2025.
- This data is from Monopar Therapeutics's annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $133.7 thousand | Q2 2017: $311.6 thousand | Q3 2017: $180.7 thousand | Q1 2018: $457.1 thousand | Q2 2018: $303.7 thousand | Q3 2018: $303.7 thousand | Q1 2019: $835.6 thousand | Q2 2019: $329.3 thousand | Q3 2019: $219.8 thousand | Q1 2020: $344.4 thousand | Q2 2020: $832.5 thousand | Q3 2020: $1.26 million | Q1 2021: $1.21 million | Q2 2021: $1.48 million | Q3 2021: $1.83 million | Q1 2022: $1.68 million | Q2 2022: $2.08 million | Q3 2022: $1.73 million | Q1 2023: $1.65 million | Q2 2023: $1.59 million | Q3 2023: $1.32 million | Q1 2024: $966.1 thousand | Q2 2024: $1.13 million | Q3 2024: $984.3 thousand | Q1 2025: $1.64 million | Q2 2025: $1.73 million | Q3 2025: $2.59 million.
- Over the full 10 years of available data (2016 to 2025), Monopar Therapeutics's Research And Development Expense has grown by 3,432.7%.
- Historical annual values: Fiscal year 2025: $9.90 million | Fiscal year 2024: $13.01 million | Fiscal year 2023: $5.60 million | Fiscal year 2022: $7.59 million | Fiscal year 2021: $6.49 million | Fiscal year 2020: $4.07 million | Fiscal year 2019: $1.97 million | Fiscal year 2018: $1.77 million | Fiscal year 2017: $935.3 thousand | Fiscal year 2016: $280.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: